| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| PPC | -0.04% | $10.79B | +32.45% | 0.00% |
| DG | 0.14% | $25.37B | -10.94% | 2.05% |
| NEUE | -0.17% | $61.16M | +29.25% | 0.00% |
| AMT | -0.22% | $105.08B | +16.75% | 2.96% |
| DUK | 0.23% | $92.39B | +19.10% | 3.55% |
| T | -0.23% | $207.81B | +53.45% | 3.83% |
| PRA | 0.48% | $1.17B | +87.59% | 0.00% |
| EZPW | 0.67% | $757.54M | +33.30% | 0.00% |
| AWK | 0.70% | $27.80B | +10.98% | 2.21% |
| LMT | 0.95% | $109.17B | +0.05% | 2.81% |
| MVO | 1.01% | $66.70M | -38.30% | 21.83% |
| STNG | 1.14% | $2.04B | -50.55% | 3.97% |
| FRO | 1.16% | $3.67B | -34.81% | 8.08% |
| KR | -1.29% | $47.17B | +41.48% | 1.81% |
| AQB | 1.30% | $2.87M | -53.40% | 0.00% |
| NAT | 1.36% | $552.67M | -34.42% | 10.99% |
| UNH | 1.41% | $295.85B | -34.54% | 2.69% |
| MKTX | 1.46% | $8.37B | +15.12% | 1.35% |
| LTM | -1.47% | $12.31B | -95.54% | 2.46% |
| QNRX | 1.59% | $5.43M | -54.36% | 0.00% |
Current Value
$6.761 Year Return
Current Value
$6.761 Year Return
Yahoo
Builds on clearances already received by FDA and EMAChina has the largest population of patients with hepatocellular carcinoma in the world BRISBANE, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company with a pipeline of first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced that the company received approval from the National Medical Products Administration (NMPA) in China to proceed with
Yahoo
BRISBANE, Calif., June 11, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company with a pipeline of first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today announced that it has entered into a definitive agreement with a single institutional investor for the purchase and sale in a registered direct offering of 739,000 shares of its common stock (or common stock equivalents), at an offering price of $6.25 per share of c
Yahoo
EMA Orphan Drug Designation (ODD) builds on U.S. Food & Drug Administration (FDA) ODD and Fast Track Designation, underscoring the urgent need for new treatment optionsThe multiple regulatory designations were granted following strong positive results from a global randomized Phase 1b/2 study in first-line HCC demonstrating superior outcomes for amezalpat combination therapy across multiple study endpoints, including overall survival in both the entire population and key subpopulations, when com
Yahoo
Presented new amezalpat mechanism-of-action data reinforcing its potential as a novel cancer treatment at the 2025 AACR Annual MeetingGranted Orphan Drug designation by FDA for TPST-1495 for the treatment of familial adenomatous polyposis (FAP)Received FDA “Study May Proceed” letter for Phase 2 trial of TPST-1495 for the treatment of FAPGranted both Orphan Drug & Fast Track designations by FDA for Amezalpat (TPST-1120) for the treatment of patients with hepatocellular carcinoma (HCC) BRISBANE, C
Yahoo
BRISBANE, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced that a presentation of new data supporting the immune component of amezalpat’s purported dual mechanism of action that reinforces its potential as a novel cancer treatment at the 2025 American Association for Cancer Research (AACR) Annual Meeting. “The data prese
Yahoo
BRISBANE, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to TPST-1495, the company’s novel dual receptor inhibitor of prostaglandin (PGE2) signaling, for the treatment of patients with Familial Adenomatous Polyposis (FAP). “Recei
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| TAIL | -42.93% | $99.49M | 0.59% |
| VIXY | -40.71% | $165.58M | 0.85% |
| XONE | -30.79% | $585.85M | 0.03% |
| BTAL | -28.33% | $295.67M | 1.43% |
| IVOL | -27.47% | $348.25M | 1.02% |
| VGSH | -24.34% | $22.77B | 0.03% |
| SPTS | -23.89% | $5.77B | 0.03% |
| UTWO | -22.21% | $379.27M | 0.15% |
| BILS | -21.86% | $3.83B | 0.1356% |
| IBTG | -21.40% | $1.92B | 0.07% |
| IBTH | -21.12% | $1.60B | 0.07% |
| SHY | -20.35% | $23.96B | 0.15% |
| ULST | -20.35% | $658.54M | 0.2% |
| GBIL | -19.81% | $6.37B | 0.12% |
| SCHO | -19.42% | $11.46B | 0.03% |
| IBTI | -19.22% | $1.06B | 0.07% |
| FXY | -19.03% | $820.31M | 0.4% |
| XHLF | -18.63% | $1.73B | 0.03% |
| FTSD | -17.97% | $231.68M | 0.25% |
| TBLL | -17.93% | $2.13B | 0.08% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| GNOM | 47.78% | $44.38M | 0.5% |
| QQQJ | 46.97% | $618.04M | 0.15% |
| KJUL | 46.74% | $119.28M | 0.79% |
| XT | 46.37% | $3.39B | 0.46% |
| RDTE | 45.86% | $137.58M | 0.97% |
| IWM | 45.66% | $63.18B | 0.19% |
| RYLD | 45.53% | $1.30B | 0.6% |
| KJAN | 45.49% | $287.49M | 0.79% |
| IWO | 45.44% | $11.53B | 0.24% |
| VTWO | 45.44% | $12.58B | 0.07% |
| IBUY | 45.19% | $150.79M | 0.65% |
| SCHA | 45.18% | $17.26B | 0.04% |
| IBB | 45.11% | $5.28B | 0.45% |
| ESML | 44.99% | $1.84B | 0.17% |
| SMMD | 44.99% | $1.45B | 0.15% |
| YYY | 44.93% | $566.36M | 3.25% |
| XBI | 44.91% | $4.84B | 0.35% |
| IWC | 44.91% | $817.74M | 0.6% |
| VIOO | 44.79% | $2.87B | 0.1% |
| BALT | 44.78% | $1.49B | 0.69% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| BCO | 42.69% | $3.90B | -8.44% | 1.06% |
| RWAY | 42.47% | $398.12M | -8.01% | 13.64% |
| CRSR | 42.31% | $998.95M | -8.53% | 0.00% |
| SLAB | 41.71% | $4.85B | +34.22% | 0.00% |
| NCZ | 41.44% | - | - | 6.28% |
| AVNT | 41.32% | $3.07B | -20.83% | 3.17% |
| NEWT | 40.81% | $307.67M | -8.21% | 6.48% |
| OLED | 40.78% | $7.45B | -26.54% | 1.07% |
| POWI | 40.74% | $3.24B | -18.40% | 1.43% |
| DCI | 40.69% | $8.23B | -0.30% | 1.57% |
| STWD | 40.49% | $6.92B | +7.32% | 9.40% |
| SYNA | 40.49% | $2.56B | -24.08% | 0.00% |
| SRG | 40.46% | $172.92M | -32.38% | 0.00% |
| ATR | 40.43% | $10.50B | +13.26% | 1.13% |
| VREX | 40.19% | $355.66M | -41.22% | 0.00% |
| TXG | 40.19% | $1.51B | -36.09% | 0.00% |
| NMAI | 40.17% | - | - | 10.90% |
| RITM | 40.08% | $6.08B | +6.90% | 10.88% |
| IR | 39.95% | $34.42B | -5.91% | 0.09% |
| ARAY | 39.92% | $140.10M | -22.29% | 0.00% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| DFDV | -19.51% | $309.70M | +2,106.40% | 0.00% |
| CBOE | -14.26% | $24.29B | +35.36% | 1.09% |
| HUSA | -14.25% | $21.26M | -8.69% | 0.00% |
| CME | -9.32% | $99.25B | +39.75% | 3.87% |
| DOGZ | -6.51% | $162.32M | -27.35% | 0.00% |
| CNK | -6.31% | $3.46B | +40.52% | 0.53% |
| ED | -5.71% | $36.31B | +13.27% | 3.35% |
| K | -5.41% | $27.71B | +40.85% | 2.85% |
| NOC | -5.26% | $72.47B | +15.13% | 1.72% |
| PULM | -4.96% | $24.14M | +230.50% | 0.00% |
| MO | -4.78% | $97.93B | +26.25% | 6.95% |
| CREG | -4.19% | $5.66M | -79.19% | 0.00% |
| IMNN | -3.89% | $15.87M | -37.00% | 0.00% |
| TU | -3.88% | $24.83B | +9.19% | 7.12% |
| VRCA | -3.54% | $55.59M | -91.95% | 0.00% |
| CNC | -3.25% | $28.19B | -14.41% | 0.00% |
| COR | -3.06% | $57.24B | +32.73% | 0.74% |
| PHYS.U | -2.40% | - | - | 0.00% |
| PSQH | -2.32% | $97.45M | -38.51% | 0.00% |
| QNTM | -2.16% | $52.38M | +102.20% | 0.00% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| IBDR | 0.03% | $3.34B | 0.1% |
| TAXF | -0.10% | $488.67M | 0.29% |
| KCCA | 0.11% | $105.90M | 0.87% |
| MMIN | 0.12% | $335.49M | 0.3% |
| SPMB | -0.13% | $6.14B | 0.04% |
| SCHP | 0.16% | $12.99B | 0.03% |
| FLCB | -0.17% | $2.59B | 0.15% |
| TLH | -0.20% | $11.41B | 0.15% |
| CGSD | 0.23% | $1.32B | 0.25% |
| TPMN | -0.26% | $30.70M | 0.65% |
| DFIP | 0.33% | $920.81M | 0.11% |
| BSCQ | -0.33% | $4.24B | 0.1% |
| BOND | -0.36% | $5.65B | 0.7% |
| FIXD | -0.39% | $3.41B | 0.65% |
| GNMA | 0.40% | $367.52M | 0.1% |
| NYF | 0.46% | $890.74M | 0.25% |
| SCHQ | 0.46% | $752.08M | 0.03% |
| LGOV | -0.48% | $681.75M | 0.67% |
| BKAG | 0.48% | $1.90B | 0% |
| SPAB | 0.53% | $8.79B | 0.03% |
